| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| 体内研究 (In Vivo) |
2,2'-联吡啶(40 mg/kg;皮下注射;一次)在高血压高血糖(2 小时内升高 53.8 mg/100 mL)后 24 小时内引起暂时性低血压,但不会导致长期糖尿病 [2]。
|
|---|---|
| 动物实验 |
Animal/Disease Models: Male Holtzman rat (6-8 weeks old)[2].
Doses: 40 mg/kg Route of Administration: subcutaneous injection; once. Experimental Results: Displayed hyperglycemic activity. |
| 药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
PYRIDINE & ITS ALKYL DERIVATIVES ARE ABSORBED FROM GI TRACT, INTRAPERITONEAL CAVITY & LUNGS. PERITONEAL ABSORPTION IS APPARENTLY ONLY SLIGHTLY MORE RAPID & COMPLETE THAN GI ABSORPTION ... IN GENERAL THE BASES ARE RAPIDLY ABSORBED THROUGH INTACT SKIN. /ALKYL DERIVATIVES OF PYRIDINE/ Metabolism / Metabolites 2,2'-BIPYRIDINE INHIBITED AROMATIC HYDROXYLATION IN MICROSOMES DERIVED FROM 3-METHYLCHOLANTHRENE TREATED RATS & ENHANCED THIS PROCESS IN MICROSOMES FROM PHENOBARBITAL SODIUM TREATED RATS. 2,2'-BIPYRIDINE PRODUCED A TYPE I BINDING SPECTRUM WITH AEROBIC MICROSOMAL FRACTIONS FROM PHENOBARBITAL SODIUM TREATED RATS & A TYPE II BINDING SPECTRUM WITH MICROSOMES FROM 3-METHYLCHOLANTHRENE TREATED RATS. |
| 毒性/毒理 (Toxicokinetics/TK) |
Interactions
2,2'-BIPYRIDINE AT CONCENTRATIONS OF 1.0-5.0 MILLIMOLE GREATLY INCREASED THE COVALENT BINDING OF (14)C-LABELED CARBON TETRACHLORIDE TO RAT LIVER MICROSOMES. BIOTRANSFORMATION OF M-FLUOROTYROSINE BY TYROSINE METABOLIC PATHWAY OF THE LIVER PLAYED AN IMPORTANT ROLE IN THE ELICITATION OF CONVULSIONS IN MICE BY M-FLUOROTYROSINE. SIMULTANEOUS ADMINISTRATION OF M-FLUOROTYROSINE & ALPHA,ALPHA-DIPYRIDYL PREVENTED THE APPEARANCE OF M-FLUOROTYROSINE INDUCED SEIZURES. Non-Human Toxicity Values LD50 Rat oral 256 mg/kg LD50 Rat sc 155 mg/kg LD50 Rat oral 100 mg/kg LD50 Rat ip 150 mg/kg For more Non-Human Toxicity Values (Complete) data for 2,2'-BIPYRIDINE (6 total), please visit the HSDB record page. |
| 参考文献 | |
| 其他信息 |
2,2'-bipyridine is a bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. It has a role as a ferroptosis inhibitor and a chelator.
2,2'-Bipyridine has been reported in Dichilus gracilis, Dichilus lebeckioides, and other organisms with data available. A reagent used for the determination of iron. Mechanism of Action 2,2'-DIPYRIDYL, A CHELATOR OF IRON(+2) & INHIBITOR OF PLATELET AGGREGATION WAS STUDIED TO DETERMINE THE MECHANISM OF ITS EFFECTS ON PLATELETS. AT LOW CONCENTRATIONS REQUIRED TO INHIBIT ARACHIDONIC ACID-MEDIATED AGGREGATION, 2,2'-DIPYRIDYL & 4,4'DIPYRIDYL-2HCL INHIBITED THE PLATELET CYCLOOXYGENASE. THE MECHANISM OF INHIBITION OF ADP-INDUCED AGGREGATION WAS INDUCED AGGREGATION, 2,2'-DIPYRIDYL DID NOT ALTER CELL ULTRASTRUCTURE, SEROTONIN OR NUCLEOTIDE CONTENT, OR INTERFERE WITH RELEASE OF ARACHIDONIC ACID-(14)C OR CALCIUM MOVEMENTS. APPARENTLY, THE INHIBITION OF CYCLOOXYGENASE BY LOW CONCENTRATIONS OF THESE COMPOUNDS IS NOT DUE TO BIDENTATE IRON CHELATION, SINCE 4,4'-DIPYRIDYL WAS ALMOST AS EFFECTIVE AS 2,2'-DIPYRIDYL, BUT IS COMPATIBLE WITH BINDING OF THESE INHIBITORS TO THE FE IN THE HEME OF THE CYCLOOXYGENASE. |
| 分子式 |
C10H8N2
|
|---|---|
| 分子量 |
156.1839
|
| 精确质量 |
156.068
|
| CAS号 |
366-18-7
|
| PubChem CID |
1474
|
| 外观&性状 |
White to off-white solid powder
|
| 密度 |
1.1±0.1 g/cm3
|
| 沸点 |
272.5±0.0 °C at 760 mmHg
|
| 熔点 |
70-73 °C(lit.)
|
| 闪点 |
107.2±12.0 °C
|
| 蒸汽压 |
0.0±0.5 mmHg at 25°C
|
| 折射率 |
1.581
|
| LogP |
1.28
|
| tPSA |
25.78
|
| 氢键供体(HBD)数目 |
0
|
| 氢键受体(HBA)数目 |
2
|
| 可旋转键数目(RBC) |
1
|
| 重原子数目 |
12
|
| 分子复杂度/Complexity |
120
|
| 定义原子立体中心数目 |
0
|
| InChi Key |
ROFVEXUMMXZLPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8N2/c1-3-7-11-9(5-1)10-6-2-4-8-12-10/h1-8H
|
| 化学名 |
2-pyridin-2-ylpyridine
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~100 mg/mL (~640.29 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 3 mg/mL (19.21 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 30.0 mg/mL 澄清的 DMSO 储备液加入到400 μL PEG300中,混匀;再向上述溶液中加入50 μL Tween-80,混匀;然后加入450 μL 生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 3 mg/mL (19.21 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 30.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 3 mg/mL (19.21 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.4029 mL | 32.0143 mL | 64.0287 mL | |
| 5 mM | 1.2806 mL | 6.4029 mL | 12.8057 mL | |
| 10 mM | 0.6403 mL | 3.2014 mL | 6.4029 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。